For these characteristics, Rolipram has entered clinical trials to measure PDE4 levels in the brain of patients with various neurological and psychiatric disorders (NCT00369798) to evaluate the different levels of PDE4 in patients with McCune-Albright Syndrome (MAS) compared to healthy controls (NCT02743377) (Table 4). The gene discussed is PDE4A; the disease is McCune-Albright syndrome.